Arch Biopartners Inc
XTSX:ARCH

Watchlist Manager
Arch Biopartners Inc Logo
Arch Biopartners Inc
XTSX:ARCH
Watchlist
Price: 2 CAD 1.52% Market Closed
Market Cap: 129.3m CAD
Have any thoughts about
Arch Biopartners Inc?
Write Note

Profitability Summary

65/100
Profitability
Score

We take all the information about a company's profitability (such as its margins, capital efficiency, free cash flow generating ability, and more) and consolidate it into one single number - the profitability score. The higher the profitability score, the more profitable the company is.

Past Growth

To be successful and remain in business, both growth and profitability are important and necessary. Net Income growth is often seen as a sign of a company's efficiency from an operational standpoint, but is influenced heavily by a company's goals and challenges and should therefore be assessed in conjunction with other metrics like revenue and operating income growth.

Margins

Profit margins represent what percentage of sales has turned into profits. Simply put, the percentage figure indicates how many cents of profit the company has generated for each dollar of sale.

Profit margins help investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Earnings Waterfall
Arch Biopartners Inc

Revenue
4.5m CAD
Operating Expenses
-10m CAD
Operating Income
-5.5m CAD
Other Expenses
-620.6k CAD
Net Income
-6.1m CAD

Margins Comparison
Arch Biopartners Inc Competitors

Country Company Market Cap Operating
Margin
Net
Margin
CA
Arch Biopartners Inc
XTSX:ARCH
128.5m CAD
-124%
-138%
US
PerkinElmer Inc
LSE:0KHE
1.4T USD
14%
9%
US
Thermo Fisher Scientific Inc
NYSE:TMO
210.8B USD
17%
14%
US
Danaher Corp
NYSE:DHR
177.9B USD
21%
18%
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW
31%
24%
CH
Lonza Group AG
SIX:LONN
39.5B CHF
13%
9%
US
IQVIA Holdings Inc
NYSE:IQV
39.9B USD
14%
9%
US
Agilent Technologies Inc
NYSE:A
39.3B USD
25%
22%
US
Mettler-Toledo International Inc
NYSE:MTD
28.1B USD
28%
21%
US
Illumina Inc
NASDAQ:ILMN
24B USD
7%
-36%
US
West Pharmaceutical Services Inc
NYSE:WST
23.7B USD
20%
17%
Country CA
Market Cap 128.5m CAD
Operating Margin
-124%
Net Margin
-138%
Country US
Market Cap 1.4T USD
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 210.8B USD
Operating Margin
17%
Net Margin
14%
Country US
Market Cap 177.9B USD
Operating Margin
21%
Net Margin
18%
Country KR
Market Cap 71.2T KRW
Operating Margin
31%
Net Margin
24%
Country CH
Market Cap 39.5B CHF
Operating Margin
13%
Net Margin
9%
Country US
Market Cap 39.9B USD
Operating Margin
14%
Net Margin
9%
Country US
Market Cap 39.3B USD
Operating Margin
25%
Net Margin
22%
Country US
Market Cap 28.1B USD
Operating Margin
28%
Net Margin
21%
Country US
Market Cap 24B USD
Operating Margin
7%
Net Margin
-36%
Country US
Market Cap 23.7B USD
Operating Margin
20%
Net Margin
17%

Return on Capital

Return on capital ratios give a sense of how well a company is using its capital (equity, assets, capital employed, etc.) to generate profits (operating income, net income, etc.). In simple words, these ratios show how much income is generated for each dollar of capital invested.

Return on Capital Comparison
Arch Biopartners Inc Competitors

Country Company Market Cap ROE ROA ROCE ROIC
CA
Arch Biopartners Inc
XTSX:ARCH
128.5m CAD
100%
-416%
124%
588%
US
PerkinElmer Inc
LSE:0KHE
1.4T USD
3%
2%
3%
3%
US
Thermo Fisher Scientific Inc
NYSE:TMO
210.8B USD
13%
6%
9%
7%
US
Danaher Corp
NYSE:DHR
177.9B USD
8%
5%
6%
5%
KR
Samsung Biologics Co Ltd
KRX:207940
71.2T KRW
10%
6%
11%
7%
CH
Lonza Group AG
SIX:LONN
39.5B CHF
6%
3%
6%
5%
US
IQVIA Holdings Inc
NYSE:IQV
39.9B USD
22%
5%
11%
9%
US
Agilent Technologies Inc
NYSE:A
39.3B USD
25%
13%
18%
17%
US
Mettler-Toledo International Inc
NYSE:MTD
28.1B USD
-648%
24%
49%
29%
US
Illumina Inc
NASDAQ:ILMN
24B USD
-37%
-18%
4%
4%
US
West Pharmaceutical Services Inc
NYSE:WST
23.7B USD
18%
13%
18%
17%
Country CA
Market Cap 128.5m CAD
ROE
100%
ROA
-416%
ROCE
124%
ROIC
588%
Country US
Market Cap 1.4T USD
ROE
3%
ROA
2%
ROCE
3%
ROIC
3%
Country US
Market Cap 210.8B USD
ROE
13%
ROA
6%
ROCE
9%
ROIC
7%
Country US
Market Cap 177.9B USD
ROE
8%
ROA
5%
ROCE
6%
ROIC
5%
Country KR
Market Cap 71.2T KRW
ROE
10%
ROA
6%
ROCE
11%
ROIC
7%
Country CH
Market Cap 39.5B CHF
ROE
6%
ROA
3%
ROCE
6%
ROIC
5%
Country US
Market Cap 39.9B USD
ROE
22%
ROA
5%
ROCE
11%
ROIC
9%
Country US
Market Cap 39.3B USD
ROE
25%
ROA
13%
ROCE
18%
ROIC
17%
Country US
Market Cap 28.1B USD
ROE
-648%
ROA
24%
ROCE
49%
ROIC
29%
Country US
Market Cap 24B USD
ROE
-37%
ROA
-18%
ROCE
4%
ROIC
4%
Country US
Market Cap 23.7B USD
ROE
18%
ROA
13%
ROCE
18%
ROIC
17%

Free Cash Flow

Free cash flow (FCF) is the money a company has left over after paying its operating expenses and capital expenditures. The more free cash flow a company has, the more it can allocate to dividends, paying down debt, and growth opportunities.

If a company has a decreasing free cash flow, that is not necessarily bad if the company is investing in its growth.

See Also

Discover More
Back to Top